Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial

A Keech; RJ Simes; P Barter; J Best; R Scott; MR Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; YA Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso; JC Ansquer; B Fraitag; N Anderson; G Hankey; S Lehto; S Mann; M Romo; LP Li; C Hennekens; S MacMahon; S Pocock; A Tonkin; L Wilhelmsen; H Akauola; F Alford; I Beinart; S Bohra; S Boyages; H Connor; D Darnell; P Davoren; F Lepre; F De Looze; A Duffield; R Fassett; J Flack; G Fulcher; S Hamwood; D Harmelin; R Jackson; W Jeffries; M Kamp; L Kritharides; L Mahar; V McCann; D McIntyre; R Moses; H Newnham; G Nicholson; R O'Brien; K Park; N Petrovsky; P Phillips; G Pinn; D Simmons; K Stanton; B Stuckey; DR Sullivan; M Suranyi; M Suthers; Y Tan; M Templer; D Topliss; JH Waites; G Watts; T Welborn; D Wilson; R Wyndham; H Haapamäki; A Kesäniemi; J Lahtela; H Levänen; J Saltevo; H Södervik; M Vanhala; J Baker; A Burton; P Dixon; J Doran; P Dunn; N Graham; A Hamer; J Hedley; P Manning; I McPherson; S Morris; C Renner; R Smith; M Wackrow; S Young; J Alcoe

Journal article

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial

A Keech, RJ Simes, P Barter, J Best, R Scott, MR Taskinen, P Forder, A Pillai, T Davis, P Glasziou, P Drury, YA Kesäniemi, D Sullivan, D Hunt, P Colman, M d'Emden, M Whiting, C Ehnholm, M Laakso, JC Ansquer Show all

Lancet | Published : 2005

DOI: 10.1016/S0140-6736(05)67667-2

Abstract

Background: Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients. Methods: We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentrat..

View full abstract